Literature DB >> 12378511

Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma.

Yun Kyung Kang1, Woo Ho Kim, Ja June Jang.   

Abstract

Aberrations of G1-S cell cycle arrest and TGF-beta/Smad pathway are critical events in human carcinogenesis. We studied alterations of both pathways by immunohistochemical staining for p53, p16, p27, cyclin D1, Rb and Smad4/Dpc4 in 42 intrahepatic cholangiocarcinomas (ICCs). Abnormal nuclear overexpression of p53 and cyclin D1 was noted in 15 (35.7%) and 26 (61.9%) cases, respectively. Total loss of p16, p27, Rb and Smad4 was detected in 15 (35.7%), 13 (31.0%), 5 (11.9%) and 19 (45.2%) cases, respectively. Forty cases (95.2%) showed aberrations of at least one of the pathways, of which 21 (50%) revealed abnormality in G1-S pathway only, 17 (40.5%) had abnormalities in both pathways and 2 (4.8%) had an abnormality in TGF-beta/Smad pathway only. Among the examined genes, loss of Smad4 was found to have a positive relationship with the pTNM stage (P < 0.05). The overall stage of the high-altered group (alterations in 2 to 5 of the genes, n = 29) was significantly higher than that of the low-altered group (alteration of one or no gene, n = 13) (P < 0.01). We also examined the expression of above genes in the accompanying biliary dysplasia and found out abnormal expression of p53, cyclin D1 or p16 in 7 out of 13 dysplastic lesions. Our data suggest that abnormal G1-S cell cycle and altered TGF-beta/Smad pathway are major events in cholangiocarcinogenesis. Moreover, there might be a possible cumulative effect of the alterations in the examined genes upon the clinical outcome of patients with resectable ICCs. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378511     DOI: 10.1053/hupa.2002.127444

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  37 in total

1.  SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas.

Authors:  Adriana Handra-Luca; Sylviane Olschwang; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2011-10-16       Impact factor: 4.064

2.  Down-regulated expression of HSP70 in correlation with clinicopathology of cholangiocarcinoma.

Authors:  Sirintip Boonjaraspinyo; Thidarut Boonmars; Sasithorn Kaewkes; Porntip Laummaunwai; Somchai Pinlaor; Watchalin Loilome; Puangrat Yongvanit; Zhiliang Wu; Anucha Puapairoj; Vajarabhongsa Bhudhisawasdi
Journal:  Pathol Oncol Res       Date:  2011-07-13       Impact factor: 3.201

Review 3.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

4.  Evaluation of positive ductal margins of biliary tract cancer in intraoperative histological examination.

Authors:  Junji Ueda; Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Masato Yoshioka; Atsushi Hirakata; Youichi Kawano; Yoshiaki Mizuguchi; Tetsuya Shimizu; Tomohiro Kanda; Hideyuki Takata; Ryota Kondo; Eiji Uchida
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

Review 5.  Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.

Authors:  Sameh Mikhail; Christopher Albanese; Michael J Pishvaian
Journal:  Am J Pathol       Date:  2015-03-05       Impact factor: 4.307

6.  Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma.

Authors:  Hong-Bing Ma; Hai-Tao Hu; Zheng-Li Di; Zuo-Ren Wang; Jing-Sen Shi; Xi-Jing Wang; Yi Li
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

Review 7.  Targeted therapy in biliary tract cancers-current limitations and potentials in the future.

Authors:  Selley Sahu; Weijing Sun
Journal:  J Gastrointest Oncol       Date:  2017-04

Review 8.  Signaling pathways as therapeutic targets in biliary tract cancer.

Authors:  Jennifer Yang; Matthew R Farren; Daniel Ahn; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Expert Opin Ther Targets       Date:  2017-03-17       Impact factor: 6.902

9.  Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth.

Authors:  Tetsuya Shimizu; Shigeki Yokomuro; Yoshiaki Mizuguchi; Yutaka Kawahigashi; Yasuo Arima; Nobuhiko Taniai; Yasuhiro Mamada; Hiroshi Yoshida; Koho Akimaru; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

Review 10.  Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas.

Authors:  Crystal S Seldon; Lauren E Colbert; William A Hall; Sarah B Fisher; David S Yu; Jerome C Landry
Journal:  World J Gastrointest Oncol       Date:  2016-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.